Filter by

Type of content

Include documents

Categories
Document type
Topics
Responsible body
Last updated
First published

Search results (27139)

Ronapreve
INN or common name: casirivimab; imdevimab
Therapeutic area (MeSH): COVID-19 virus infection
Withdrawal of marketing authorisation:
Last updated: 23 January 2026
Revision: 9
MedicineHumanWithdrawn
Austedo
INN or common name: deutetrabenazine
Therapeutic area (MeSH): Tardive Dyskinesia
Marketing authorisation issued:
Last updated: 23 January 2026
Additional monitoring
MedicineHumanAuthorised
Nexviadyme
INN or common name: avalglucosidase alfa
Therapeutic area (MeSH): Glycogen Storage Disease Type II
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 6
Additional monitoring
MedicineHumanAuthorised
Travatan
INN or common name: travoprost
Therapeutic area (MeSH): Glaucoma, Open-Angle; Ocular Hypertension
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 32
MedicineHumanAuthorised
Simbrinza
INN or common name: brinzolamide; brimonidine tartrate
Therapeutic area (MeSH): Ocular Hypertension; Glaucoma, Open-Angle
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 13
MedicineHumanAuthorised
Nevanac
INN or common name: nepafenac
Therapeutic area (MeSH): Pain, Postoperative; Ophthalmologic Surgical Procedures
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 21
MedicineHumanAuthorised
Elahere
INN or common name: mirvetuximab soravtansine
Therapeutic area (MeSH): Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 2
Additional monitoring
Orphan
MedicineHumanAuthorised
Bimzelx
INN or common name: bimekizumab
Therapeutic area (MeSH): Psoriasis
Marketing authorisation issued:
Last updated: 23 January 2026
Revision: 12
Additional monitoring
MedicineHumanAuthorised
EMEA-002828-PIP01-20 - paediatric investigation plan
Active substance: firsocostat; cilofexor
Therapeutic area: Hepatobiliary disorders
Pharmaceutical form(s): Film-coated tablet
Route(s) of administration: Oral use
Decision number: EMA/PE/0000239079
Decision date: 16 May 2025
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance check done: No
Last updated: 23 January 2026
PIPHuman